LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Home・Elenco Azioni・TG Therapeutics Inc

TG Therapeutics Inc

Aperta

SettoreSettore sanitario

30.61 0.62

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.53

Massimo

30.73

Metriche Chiave
By Trading Economics
Entrata	363M 391M
Vendite	21M 162M
P/E Media del settore	11.13 80.03
Margine di Profitto	241.727
Dipendenti	374
EBITDA	-4.9M 33M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+47.88% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-451M 4.9B
Apertura precedente	29.99
Chiusura precedente	30.61

Notizie sul Sentiment di mercato

By Acuity

23%

77%

51 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

N/A / 34.86 Supporto e resistenza

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 dic 2025, 22:13 UTC

Utili

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Utili

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

I principali Market Mover

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Utili

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Discorsi di Mercato

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Discorsi di Mercato

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Discorsi di Mercato

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Utili

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Utili

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Utili

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

47.88% in crescita

Previsioni per 12 mesi

Media 45 USD 47.88%

Alto 60 USD

Basso 11 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

51 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.